Literature DB >> 10946277

MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300.

T J Sisk1, T Gourley, S Roys, C H Chang.   

Abstract

The MHC class II transactivator (CIITA) activates the expression of multiple genes involved in Ag presentation, but inhibits Th2-type cytokine production, including IL-4, during Th1 cell differentiation. Th1 cells derived from CIITA-deficient mice produce both Th1- and Th2-type cytokines, and the introduction of CIITA to Th2 cells down-regulates Th2-type cytokine gene transcription. Here we show that the IL-4 promoter is regulated by multiple protein-protein interactions among CIITA, NF-AT, and coactivator CBP/p300. The introduction of CBP/p300 and NF-AT enhances the IL-4 promoter activity, and this activation was repressed by CIITA. Furthermore, our data show that CIITA competes with NF-AT to bind CBP/p300 and that this competition dramatically influences transcriptional activation of the IL-4 promoter. We identified two domains of CIITA that interact with two distinct domains of CBP/p300 that are also recognized by NF-AT. CIITA mutants that retain the ability to interact with CBP/p300 are sufficient to inhibit NF-AT-mediated IL-4 gene expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946277     DOI: 10.4049/jimmunol.165.5.2511

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  Self-association of CIITA and its transactivation potential.

Authors:  T J Sisk; S Roys; C H Chang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

5.  Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Authors:  Giovanna Tosi; Greta Forlani; Vibeke Andresen; Marco Turci; Umberto Bertazzoni; Genoveffa Franchini; Guido Poli; Roberto S Accolla
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

6.  TNF-α-308G/A polymorphism associated with TNF-α protein expression in patients with diabetic nephropathy.

Authors:  Yan Peng; Liu-Juan Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

7.  Regulation of IL-17 expression by the developmental pathway of CD4 T cells in the thymus.

Authors:  M Hanief Sofi; Zhiping Liu; Lingqiao Zhu; Qiao Yu; Mark H Kaplan; Cheong-Hee Chang
Journal:  Mol Immunol       Date:  2010-01-18       Impact factor: 4.407

8.  Elevated IL-6 expression in CD4 T cells via PKCtheta and NF-kappaB induces Th2 cytokine production.

Authors:  M Hanief Sofi; Wei Li; Mark H Kaplan; Cheong-Hee Chang
Journal:  Mol Immunol       Date:  2009-01-31       Impact factor: 4.407

9.  Overexpression of CIITA in T cells aggravates Th2-mediated colitis in mice.

Authors:  Tae Woon Kim; Hyo Jin Park; Eun Young Choi; Kyeong Cheon Jung
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

10.  Mycobacteria inhibit nitric oxide synthase recruitment to phagosomes during macrophage infection.

Authors:  Barbara H Miller; Rutilio A Fratti; Jens F Poschet; Graham S Timmins; Sharon S Master; Marcos Burgos; Michael A Marletta; Vojo Deretic
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.